Calliditas Therapeutics AB is a Sweden-based biopharmaceutical company focused on developing and commercializing treatments for rare kidney and liver diseases with significant unmet medical need. Headquartered in Stockholm, the company operates globally through a combination of in-house R&D and strategic partnerships.
Its lead product is Nefecon, a targeted-release formulation of budesonide designed to modulate mucosal immunity in IgA nephropathy (IgAN). Nefecon is marketed as TARPEYO in the United States and as KINPEYGO in the European Union. Calliditas is also advancing setanaxib, an oral NOX1/4 inhibitor, in clinical programs for fibrotic and inflammatory conditions, including primary biliary cholangitis and select oncology settings.
Brings acquired specialty-pharma units into a single global management to pursue niche immunology, nephrology, transplant and infectious disease markets; targets ¥300bn by FY2030.
The acquisition enhances Asahi Kasei's pharmaceutical platform in severe infectious diseases, leveraging existing infrastructure for growth and expanding its treatment portfolio.
AK1960, a novel ETA receptor antagonist with a new core structure, shows high ETA selectivity and kidney-disease efficacy in animals and has advanced to Phase I for refractory diseases.
AK1960, an ETA receptor antagonist, enters Phase I trials for refractory diseases, leveraging Alchemedicine's HiSAP™ platform and partnerships with Calliditas and Veloxis.
